QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

Summary

QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2 diabetes will result in improved glycemic control, reduced exogenous insulin requirement, increased lean fat mass and improved pancreatic beta-cell function.

Timeline

Start

2011-11

Primary completion

2012-05

Completion

2012-06

Outcome

Met primary endpoint

registry analysis (unspecified test); Metformin + Insulin vs QR-Bromocriptine + Metformin + Insulin; p = 0.004; ANOVA NCT01474018 ↗

Drugs

Indications